ExpreS2ion Biotech Holding AB · OMXSTO:EXPRS2

ExpreS2ion Biotech Holding AB financial statements

ExpreS2ion Biotech Holding AB's income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in SEK

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue3.66M3.01M7.05M5.09M12.2M5.26M13.8M8.87M9.79M4.65M
Cost of revenue46.5M5.68M3.65M5.08M7.51M6.10M3.40M2.75M2.19M1.35M
Gross profit-42.8M-2.67M3.40M5.00K4.72M-843.0K10.4M6.12M7.60M3.30M
Research and development9.98M26.7M51.4M71.3M9.81M216.0K
Selling, general and administrative27.0M27.0M43.3M41.3M3.52M21.4M8.54M7.18M5.93M4.17M
Operating income-52.8M-67.7M-106.0M-127.6M-48.4M-31.2M-16.3M-18.3M-11.4M-9.16M
Depreciation and amortization1.47M1.64M1.60M1.22M1.81M2.92M2.88M2.62M2.28M1.49M
EBITDA-51.4M-66.1M-104.4M-126.4M-46.6M-28.3M-13.4M-15.6M-9.15M-7.67M
Interest expense451.0K727.0K501.0K871.0K156.0K3.53M971.0K617.0K461.0K557.0K
Income before tax-44.2M-44.6M-100.0M-126.6M-47.5M-34.9M-19.1M-18.9M-11.8M-9.41M
Income tax-6.09M-8.53M-8.57M-7.98M-3.59M-3.21M-2.38M-2.03M-1.92M-874.0K
Net income-38.1M-36.0M-91.4M-118.6M-43.9M-31.7M-16.7M-16.8M-9.84M-8.54M
Earnings per share, basic-13.39-13.88-79.22-125.71-1.36-1.66-1.03-1.14-0.81-30.07

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents47.6M81.5M57.6M111.0M37.1M106.8M5.42M6.25M1.51M6.26M
Short-term investments4.44M-1.53M101.8M-966.0K-933.0K-682.0K
Receivables9.97M5.06M2.35M10.8M7.11M5.10M4.35M4.05M4.21M5.31M
Inventory-4.05M-4.21M1
Current assets57.5M95.0M68.7M131.9M146.5M112.5M10.1M10.8M6.05M11.8M
Property, plant and equipment465.0K1.53M1.77M910.0K1.21M1.29M1.19M993.0K632.0K679.0K
Goodwill016.0K00194.0K802.0K1.38M1.90M2.40M
Total assets65.1M104.5M78.7M137.4M152.0M118.9M18.7M21.0M17.2M24.6M
Accounts payable4.04M8.47M1.84M12.2M1.69M2.08M1.08M607.0K470.0K799.0K
Current liabilities28.3M38.2M11.4M31.4M7.46M18.2M12.2M5.04M2.36M3.58M
Long-term debt3.48M5.27M6.38M6.06M6.32M
Total debt2.21M1.80M1.71M1.85M5.39M7.16M7.87M6.99M6.40M5.87M
Total liabilities29.4M40.1M13.3M34.0M11.6M24.3M19.8M12.7M10.5M11.7M
Shareholders' equity35.7M64.8M65.4M103.3M140.3M94.5M-1.08M8.30M6.74M12.9M
Shares outstanding2.84M2.60M1.15M943.5K32.2M19.1M16.2M14.7M12.2M283.9K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-40.9M-33.9M-100.9M-99.6M-45.6M-18.2M-12.7M-12.9M-8.61M-7.02M
Capital spending0-870.0K-2.02M-383.0K-715.0K-885.0K-679.0K-813.0K-206.0K-720.0K
Free cash flow-40.9M-34.8M-102.9M-100.0M-46.4M-19.1M-13.4M-13.7M-8.81M-7.74M
Cash from investing021.3M-2.02M105.3M-100.9M-1.08M-679.0K-813.0K-206.0K-720.0K
Cash from financing10.8M34.9M47.8M61.5M74.5M123.4M12.6M18.6M3.98M14.7M
Share buybacks12.1M42.3M60.7M76.0M83.3M143.2M8.00M19.3M-402.0K-2.11M
Change in cash-34.0M23.9M-53.4M73.9M-69.7M101.4M-837.0K4.75M-4.75M5.94M